Page 1

For personal use only impedimedⓇ 28 January 2021 ASX ANNOUNCEMENT APPENDIX 4C - Quarter Ended 31 December 2020 ( Q2 FY'21 ) Brisbane , Australia - ImpediMed Limited ( ASX.IPD ) , a medical technology company that uses bioimpedance spectroscopy ( BIS ) technology to generate powerful data to maximise patient health , today released its Appendix 4C - Quarterly Cash Flow report for the period ended 31 December 2020 . Revenue Summary : • Record quarter for Total Revenue for Q2 FY'21 of $ 2.1 million , + 40 % the previous corresponding period ( pcp ) ( Q2 FY'20 : $ 1.5 million ) and + 40 % quarter over quarter . Record quarter for SOZOⓇ Revenue for Q2 FY'21 of $ 1.9 million , + 58 % pcp ( Q2 FY'20 : $ 1.2 million ) and + 36 % quarter over quarter . Record quarter for SOZO SaaS Revenue for Q2 FY'21 of $ 1.3 million , + 63 % pcp and + 18 % quarter over quarter . O о о SOZO SaaS Revenue of $ 1.1 million from Core Business ' , + 17 % pcp and + 4 % quarter over quarter . The appreciating AUD is underrepresenting the strength of the SaaS Revenue from the Core Business in the translated results . When reported in USD , SOZO SaaS Revenue from the Core Business was + 34 % pcp and + 19 % quarter over quarter . SOZO SaaS Revenue of $ 0.2 million from Clinical Business " . Cash Flow Summary : Cash on hand as at 31 December 2020 of $ 19.0 million . Cash receipts from customers for the quarter of $ 2.0 million . Receipt of an additional $ 6.6 million from the exercise of options issued to subscribers in the entitlement offer ( with potential for up to a further $ 9.1 million to be raised by 31 March 2021 , from remaining options issued in the offer ) . Net operating cash outflows of $ 2.0 million . о Net operating cash outflows of $ 6.6 million for the six - months ending 31 December 2020 , significantly better than the forecasted $ 8.0 million net operating cash outflow announced to the market on 27 October 2020 . Effective 1 January 2021 , the temporary reductions to the CEO and Executives ' cash salaries were removed . The Company expects net operating cash outflows to remain below $ 4.0 million for Q3 FY'21 , which includes some additional spend on product improvement for heart and renal failure . Related Parties : During the quarter , the Company issued shares to Directors as equity- based remuneration in lieu of cash , as described in Item 6 of the Appendix 4C . Operational Summary and Key SaaS Metrics : • • Record quarter for Patient Tests , with over 28,000 recorded in Q2 FY'21 , + 33 % pcp and + 9 % quarter over quarter . Annual Recurring Revenue of $ 7.8 million , + 86 % pcp and + 30 % quarter over quarter . ○ ARR of $ 4.9 million from Core Business , + 17 % pcp and + 4 % quarter over quarter . о ARR of $ 2.9 million from Clinical Business .